LECT2 and fatty liver disease: Gemigliptin (a novel DPP4 inhibitor) might mitigate hepatic steatosis and IR, suggesting a direct protective effect on NAFLD progression, which inhibits the expression of LECT2 through AMPK-dependent and JNK-dependent mechanisms (36).